What is Lactiga?
Lactiga is a pioneering biotechnology enterprise dedicated to the advancement of immunoscience through the development of innovative mucosal antibody therapies. The company distinguishes itself by utilizing secretory IgA antibodies, naturally derived from human milk, to bolster mucosal immunity. This methodology represents a fundamental shift in therapeutic delivery, moving away from traditional systemic administration to target the primary entry points of pathogens. By focusing on chronic respiratory disorders and immune deficiencies, Lactiga is addressing critical gaps in current treatment paradigms, aiming to provide more effective, targeted interventions for vulnerable patient populations. Their work sits at the intersection of immunology and advanced drug delivery, positioning them as a high-potential player in the biopharmaceutical sector.
How much funding has Lactiga raised?
Lactiga has raised a total of $1.6M across 1 funding round:
Angel/Seed
$1.6M
Angel/Seed (2022): $1.6M with participation from 1517 Fund I
Key Investors in Lactiga
1517 Fund I
1517 Fund is a venture capital and private equity firm that specializes in pre-seed and seed-stage investments, focusing on supporting early-stage founders and disruptive technologies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lactiga?
With the recent infusion of capital, Lactiga is expected to prioritize the scaling of its therapeutic antibody platform and the advancement of its lead candidates through preclinical and early-stage clinical milestones. The company's strategic roadmap likely involves expanding its laboratory infrastructure and strengthening its intellectual property portfolio surrounding secretory IgA technology. As the firm transitions from a research-focused entity to a clinical-stage developer, the focus will remain on optimizing delivery mechanisms and establishing partnerships that can facilitate the commercialization of its mucosal therapies. Investors will be closely monitoring the company's ability to translate its scientific breakthroughs into measurable patient outcomes, which will be essential for securing subsequent rounds of growth financing and achieving long-term sustainability in the competitive biotechnology landscape.
See full Lactiga company page
